Versartis [VSAR] to Ring The NASDAQ Stock Market Closing Bell in Celebration of IPO

        Print
| Source: The NASDAQ OMX Group, Inc.

ADVISORY, March 21, 2014 (GLOBE NEWSWIRE) --

What:

Versartis [VSAR], a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO) which occurred on The NASDAQ Stock Market today March 21.

In honor of the occasion, Jeff Cleland, Co-Founder & Chief Executive Officer will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Friday, March 21, 2014 – 3:45 p.m. to 4:00 p.m. ET   

Contact:
Debra Bannister
(530) 676-7373
media@versartis.com

NASDAQ MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit our Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A LiveStream of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live

Or

http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Versartis [VSAR]:

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The company is currently completing a Phase 2a clinical trial of VRS-317 in children with GHD. Further information on Versartis can be found at www.versartis.com.

About NASDAQ OMX Group:

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,200 listed companies with a market value of over $8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.   

-NDAQA-